Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
...agnosis
...e 1. Risk Factors for Multidrug-Resistant Patho...
...crobiologic Met...
...suggest noninvasive sampling with semiquantit...
...oninvasive sampling with semiquantitati...
...DSA suggest that patients with suspected HAP (n...
...markers...
...patients with suspected HAP/VAP, A...
...with suspected HAP/VAP, ATS and IDSA rec...
...s with suspected HAP/VAP, ATS and IDSA r...
...r patients with suspected HAP/VAP, ATS and IDSA...
Treatment
...eatment...
...nitia...
...patients with ventilator-associated tracheobronc...
...SA recommend that all hospitals regularly gene...
ATS and IDSA recommend that empiric treatment r...
...n patients with suspected VAP, ATS and I...
...ggest including an agent active against MRSA...
...gest including an agent active agai...
...empiric coverage for MRSA is indicated...
...ic treatment that includes coverage for MSSA (a...
...gest prescribing two antipseudomonal...
...gest prescribing one antibiotic active a...
...with suspected VAP, ATS and IDSA suggest avo...
...ith suspected VAP, ATS and IDSA sugg...
...IDSA recommend that empiric antibiotic regimens b...
...TS and IDSA recommend that all hospitals...
...eing treated empirically for HAP, A...
...patients with HAP who are being treated e...
...atients with HAP who require empiric coverage...
For patients with HAP who are being treated em...
...with HAP who are being treated empirically, ATS a...
...with HAP who are being treated empirica...
...s with HAP who are being treated empirically,...
...ptimizat...
...patients with HAP/VAP, ATS and IDSA sug...
...nhaled Antibioti...
...patients with VAP due to Gram-negative...
...gen-Specific Therapy...
...DSA recommend that MRSAHAP/VAP be tr...
...patients with HAP/VAP due to P. aeruginosa...
...with HAP/VAP due to P. aeruginosa, ATS and IDS...
...tients with HAP/VAP due to P. aeruginosa who...
...tients with HAP/VAP due to P. aeruginosa who...
...tients with HAP/VAP due to P. aerugi...
...with HAP/VAP due to extended-spectrum β-lac...
...s with HAP/VAP caused by Acinetobacter sp...
...atients with HAP/VAP caused by Aci...
...A suggest adjunctive inhaled colistin. ( W...
...with HAP/VAP caused by Acinetobact...
...nts with HAP/VAP caused by Acineto...
...ith HAP/VAP caused by a carbapenem-resi...
and ATS and IDSA suggest adjunctive inhaled colis...
...patients with VAP, ATS and IDSA recommen...
...nts with HAP, ATS and IDSA recomme...
...ients with HAP/VAP, ATS and IDSA suggest that anti...
...nts with HAP/VAP, ATS and IDSA suggest us...
...patients with suspected HAP/VAP, ATS and...
...le 2. Recommended Initial Empiric Antibiot...
...Empiric Treatment Options for Suspec...